Lenalidomide 10 mg

DRUG4 trials

Conditions

Amyloid PlaqueCognitive DysfunctionCognitive Impairment, MildInflammation, BrainMyelodysplastic SyndromesNeurodegenerationNeurodegenerative Disease, HereditaryOral Ulcer

Phase 2

MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

CompletedNCT04032626

St. Joseph's Hospital and Medical Center, PhoenixAmyloid Plaque, Cognitive Dysfunction, Cognitive Impairment, Mild +2

Start: 2020-07-22End: 2025-05-31Updated: 2026-06-10

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

Not yet recruitingNCT06177028

St. Joseph's Hospital and Medical Center, PhoenixAmyloid Plaque, Cognitive Dysfunction, Cognitive Impairment, Mild +2

Start: 2025-06-01End: 2027-01-02Target: 45Updated: 2025-05-18

Phase 3

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

CompletedNCT00179621

Celgene CorporationMyelodysplastic Syndromes

Start: 2005-07-31End: 2010-06-30Updated: 2011-04-14

Unknown Phase

Lenalidomide in the Treatment of Mucosal Behçet's Syndrome

RecruitingNCT05449548

Peking Union Medical College HospitalOral Ulcer

Start: 2023-04-01End: 2026-12-31Target: 42Updated: 2026-06-22

Related Papers

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

2017-06-265 citations

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

Haematologica2014-03-28132 citations

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

2011-07-13350 citations